Using PET/CT to monitor head and neck cancer after treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of 18F-fluorodeoxy-D-glucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) in detecting recurrences of head and neck squamous cell carcinoma (HNSCC) in patients who have completed curative treatment. The research focuses on patients who have undergone radiotherapy for HNSCC, aiming to enhance early detection of potential cancer recurrence. By following established guidelines, the study seeks to improve patient outcomes through timely interventions based on PET/CT findings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Informed consent
* Age above 18
* Completed curative treatment for HNSCC of the oral cavity, nasopharynx, oropharynx, hypopharynx or larynx

Exclusion Criteria:

* Patient refusal
* Patients with clinical N0 neck
* Patients who had neck dissections prior to radiotherapy
* Patients who are clinical inoperable for any reason

Where it's running

• Department of Otorhinolaryngology, Head & Neck Surgery and Audiology, Rigshospitalet
  Copenhagen, Copenhagen, Denmark Recruiting

Study contacts

• Study coordinator: Jacob H Rasmussen, MD; PhD
• Email: jacob.hoeygaard.rasmussen.01@regionh.dk
• Phone: +4535453251

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Neoadjuvant therapy with nimotuzumab, toripalimab, nab-paclitaxel, and cisplatin for locally advanced head and neck cancer

  This study tests a pre-surgery treatment combining targeted therapy, immunotherapy, and chemotherapy to see if it helps patients with locally advanced, resectable head and neck squamous cell carcinoma.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Hebei, Hebei · NCT07906587

• Omni 128 cm PET/CT imaging system: comparing new scanner with standard PET/CT

  This study tests a new Omni 128 cm PET/CT scanner by having adults with a planned clinical PET/CT also undergo an extra research scan to compare image quality.

  Recruiting GE Healthcare · Stanford, California · NCT07857161

• ICG with near-infrared imaging to visualize head and neck cancer during surgery

  This study tests whether first-window indocyanine green fluorescence seen during surgery matches the cancer extent seen on pathology in patients with head and neck squamous cell carcinoma.

  Recruiting Phase 2 Washington University School of Medicine · St Louis, Missouri · NCT07825597

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

• Online Sharing for Head & Neck Cancer Support

  A mobile app designed for adults with head and neck cancer undergoing radiotherapy to see if daily social sharing and peer interaction can help reduce psychological distress.

  Recruiting West China Hospital · Chengdu, Sichuan · NCT07766226

• Telisotuzumab Adizutecan with Pembrolizumab as first-line treatment for recurrent or metastatic head and neck cancer

  This study tests a combination treatment to see if it helps people with newly diagnosed recurrent or metastatic head and neck squamous cell carcinoma who express the c-Met protein.

  Recruiting at 5 sites Phase 2 AbbVie · Duarte, California and 4 other locations · NCT07744126

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.